中文

Nurix Therapeutics (NRIX)

Biotech

Close on Nov 4, 2026 (from our latest article): $15.95

Market value
$1.7Bat the Nov 4 close
Revenue growth
+739%12 months to Aug 31, 2026 (10-Q)
FCF margin
53%12 months to Aug 31, 2026 (10-Q)
Net cash
$1.1Bat Aug 31, 2026
Worst fall since listing
−91.5%Jan 19, 2021 to Oct 25, 2023; not back to that high (−72.9% now)

About the company

Latest

  • Down 38.2% Move
    Nurix falls 38% as Sanofi ends a partnered drug program

The Long View

What the filings say about the story, dilution and cash runway.

No Long View yet. Request one →

Our View Opinion

Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.

No Our View yet. Request one →

More of our coverage that names Nurix Therapeutics

Long-term fundamentals

Annual results for Nurix Therapeutics, FY2019–FY2025, as reported in its 10-K filings. Nurix Therapeutics's fiscal year ends in late November; FY2025 is the year that ended in November 2025.

Revenue and free cash flow

Revenue went from $31M in FY2019 to $84M in FY2025. Free cash flow was positive in 0 of the 7 years shown; FY2025: −$263M. Each year's figures are in the table below. −$300M−$200M−$100M$0$100M ’19 ’20 ’21 ’22 ’23 ’24 ’25

Revenue went from $31M in FY2019 to $84M in FY2025.

Free cash flow was positive in 0 of the 7 years shown; FY2025: −$263M.

Margins

Margins are not charted: in FY2025 the operating loss (−$286M) was larger than revenue ($84M). The table has each year's figures.

Diluted share count

The diluted share count rose 102% from FY2021 to FY2025, to 87M. Each year's figures are in the table below. 40M50M60M70M80M90M ’21’22’23’24’25

The diluted share count rose 102% from FY2021 to FY2025, to 87M.

Results and cash flow

Fiscal yearRevenueGross marginOperating marginNet incomeOperating cash flowCapital spendingFree cash flow
FY2025$84M—−340%−$264M−$249M$14M−$263M
FY2024$55M—−391%−$194M−$173M$9M−$182M
FY2023$77M—−201%−$144M−$81M$8M−$90M
FY2022$39M—−476%−$180M−$160M$12M−$172M
FY2021$30M—−396%−$117M−$84M$6M−$90M
FY2020$18M—−365%−$43M−$0.1M$5M−$5M
FY2019$31M—−71%−$22M$0.6M$2M−$1M

Shares, cash, debt and payouts

Fiscal yearDiluted sharesCash and investmentsDebtStock-based payDividends paidBuybacks
FY202587M$593M—$38M——
FY202467M$610M—$34M——
FY202354M$295M—$34M——
FY202249M$309M—$28M——
FY202143M$296M—$16M——
FY2020—$281M—$4M——
FY2019—$38M—$0.5M——

Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 4, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.

Returns by year

YearNRIXS&P 500
2019—+31.5%
2020+73.0%†+18.4%
2021−11.9%+28.7%
2022−62.1%−18.1%
2023−6.0%+26.3%
2024+82.6%+25.0%
2025+0.7%+17.9%
2026 to date−28.3%+5.9%

Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. † From the first close after listing (Jul 24, 2020); "—" is before listing. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.

Other companies we cover in Biotech

Show all 17

Questions about Nurix Therapeutics

Why did Nurix Therapeutics stock fall on Nov 4, 2026?
Nurix fell 38% after saying Sanofi will stop the early-stage trial of SAR448272, a drug Nurix discovered, and end the program. Nurix no longer expects about $455 million of possible milestones or any royalties from it. Nurix gave no reason; Leerink Partners said Sanofi's investor relations cited nonclinical findings, BioSpace reported. Nurix says its $1.1 billion of cash still lasts into the second half of 2029. Read the article →